Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROLINGUAL PUMPSPRAY vs ISMO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (c GMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Treatment of acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack)
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Terminal elimination half-life of nitroglycerin is 1–4 minutes; however, clinical hemodynamic effects last longer due to active metabolites and tissue distribution.
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Metabolized primarily in the liver by the enzyme glutathione nitrate reductase, and also by red blood cells and vascular smooth muscle. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate, which have minimal vasodilatory activity.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Renal excretion of inactive metabolites (nitrate ions) accounts for approximately 80% of elimination; biliary/fecal excretion is minimal (less than 5%).
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Approximately 60% bound, primarily to albumin.
Approximately 30% bound to plasma proteins, primarily albumin.
3.3 L/kg, indicating extensive extravascular distribution.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
Sublingual spray: approximately 40% (due to first-pass metabolism in liver and gastrointestinal tissues after swallowing).
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
Dose reduction may be needed in severe hepatic impairment (Child-Pugh C); start with lowest effective dose.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Safety and efficacy not established; not recommended for use in pediatric patients.
Safety and efficacy not established; no standard dosing recommendations.
Initiate with lowest effective dose; increased sensitivity to hypotension due to age-related changes in baroreceptor reflexes.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
Coadministration with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) is contraindicated due to the risk of severe hypotension, syncope, and myocardial ischemia.
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension: May cause severe hypotension in patients with hypovolemia or low systolic blood pressure.,Hepatic impairment: Use with caution in patients with severe hepatic disease.,Headache: Common and may be severe; tolerance may develop.,Sublingual administration: Do not inhale; spray onto or under the tongue.,Overuse: Excessive use may result in tolerance and reduced efficacy.
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Hypersensitivity to nitroglycerin or any component of the formulation,Concurrent use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis or cardiac tamponade
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
Avoid alcohol consumption as it may increase hypotensive effects. No specific food interactions; consult healthcare provider regarding dietary concerns.
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
Nitroglycerin (NTG) is classified as FDA Pregnancy Category C. Animal reproduction studies are inadequate. In first trimester, limited human data show no consistent association with major malformations. During second and third trimesters, use is reserved for acute hypertensive crises or pulmonary edema; potential risks include maternal hypotension leading to uteroplacental hypoperfusion and fetal hypoxia. Avoid near term due to risk of maternal hypotension and possible fetal distress.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
No human data on NTG excretion in breast milk. M/P ratio is unknown. Based on molecular weight (227.09 Da) and short half-life (1-3 min), transfer is likely minimal. Use with caution in breastfeeding only if clearly needed; monitor infant for hypotension or methemoglobinemia (rare).
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
No systematic pharmacokinetic studies in pregnancy. Physiological changes (increased plasma volume, renal clearance) may alter distribution. No dose adjustment recommendations exist; use lowest effective dose. Initial dose: 1-2 sprays (0.4-0.8 mg) sublingually, repeat every 5 minutes up to 3 doses. Monitor for exaggerated hypotension due to decreased vascular resistance in pregnancy.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
Nitrolingual Pumpspray (nitroglycerin) is a sublingual spray for acute angina. Onset of action is 1-3 minutes. Do not shake before use. Prime pump with 5 sprays if new or not used for 6 weeks. Avoid concurrent use of PDE5 inhibitors (e.g., sildenafil) due to severe hypotension. Monitor for hypotension, syncope, and headache. Tolerance develops with frequent use; provide nitrate-free interval.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Use 1-2 sprays at the first sign of angina, under the tongue, not inhaled.,Do not shake the bottle before use.,Prime the pump with 5 sprays if new or not used for 6 weeks.,Sit down when using to avoid fainting from low blood pressure.,Seek emergency if pain not relieved after 3 doses (5 minutes apart).,Avoid alcohol and erectile dysfunction drugs (e.g., sildenafil, tadalafil).
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
No interactions on record
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROLINGUAL PUMPSPRAY vs ISMO, answered by our medical review team.
NITROLINGUAL PUMPSPRAY is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (c GMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.. ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROLINGUAL PUMPSPRAY and ISMO depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROLINGUAL PUMPSPRAY is: 1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.. The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROLINGUAL PUMPSPRAY and ISMO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROLINGUAL PUMPSPRAY is classified as Category C. Nitroglycerin (NTG) is classified as FDA Pregnancy Category C. Animal reproduction studies are inadequate. In first trimester, limited human data show no consistent association wit. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.